ARRA funds awarded to RetroVirox to continue antiviral programs
ARRA funds awarded to RetroVirox to continue antiviral programs
May 1, 2010
San Diego, CA - RetroVirox, Inc., announced today an award of $356,280 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This award, issued under the American Recovery and Reinvestment Act of 2009 (ARRA), will be used to expand R&D efforts at RetroVirox to discover antiretroviral agents against novel targets.
This is the third award from NIAID since the company started operations early in 2009. Combined, RetroVirox has received $870,000 from the National Institutes of Health.
About RetroVirox
RetroVirox, Inc. is a privately held company with headquarters in San Diego, California. RetroVirox is developing novel drugs to treat some of the most challenging human pathogens, including HIV and HCV. The company utilizes unconventional approaches to discover viral entry inhibitors with potential to be developed into first-in-class anti-viral drugs. The company was founded by a group of leading scientists in the fields of virology and drug discovery and is currently raising Series A financing.
For more information email us at info@retrovirox.com
# # #